Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).

Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R

Open source

DOI: 10.1002/gps.4583
Published: 2017 Dec
Container: International journal of geriatric psychiatry
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/gps.4583,
  title = {Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).},
  author = {Knapp M and King D and Romeo R and Adams J and Baldwin A and Ballard C and Banerjee S and Barber R and Bentham P and Brown RG and Burns A and Dening T and Findlay D and Holmes C and Johnson T and Jones R and Katona C and Lindesay J and Macharouthu A and McKeith I and McShane R and O'Brien JT and Phillips PPJ and Sheehan B and Howard R},
  year = {2017},
  journal = {International journal of geriatric psychiatry},
  doi = {10.1002/gps.4583},
  url = {https://doi.org/10.1002/gps.4583}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
AU  - Knapp M
AU  - King D
AU  - Romeo R
AU  - Adams J
AU  - Baldwin A
AU  - Ballard C
AU  - Banerjee S
AU  - Barber R
AU  - Bentham P
AU  - Brown RG
AU  - Burns A
AU  - Dening T
AU  - Findlay D
AU  - Holmes C
AU  - Johnson T
AU  - Jones R
AU  - Katona C
AU  - Lindesay J
AU  - Macharouthu A
AU  - McKeith I
AU  - McShane R
AU  - O'Brien JT
AU  - Phillips PPJ
AU  - Sheehan B
AU  - Howard R
PY  - 2017
JO  - International journal of geriatric psychiatry
DO  - 10.1002/gps.4583
UR  - https://doi.org/10.1002/gps.4583
ER  -

APA

M, K., D, K., R, R., J, A., A, B., C, B., S, B., R, B., P, B., RG, B., A, B., T, D., D, F., C, H., T, J., R, J., C, K., J, L., A, M., I, M., R, M., JT, O., PPJ, P., B, S., & R, H. (2017). Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).. International journal of geriatric psychiatry. https://doi.org/10.1002/gps.4583

Source records

pubmed · retrieved 2026-09-26T12:42:57.847Z